Article

Development of an Accurate and Rapid Antigen Assay for COVID-19 Diagnostics Using Saliva

Camille Troup^{1,2}, Debnath Mukhopadhyay^{1,3}, Tania Chakrabarty^{1,4}, Anup Madan^{1,5}, Sri Satyanarayana^{1,6}, Shreefal Mehta^{1,7}, and Su Dwarakanath^{1*}

Kaya17, Livermore CA, ²camille@kaya17.com, ³debms12@yahoo.com, ⁴chkrbrty2002@yahoo.com, ⁵Anup@kaya17.com, ⁶Sri@kaya17.com, ⁷shreefal@kaya17.com, *Correspondence: su@kaya17.com

Abstract: The global outbreak of COVID-19 highlighted the need for rapid and accurate diagnostic testing to control the spread of this highly contagious disease (1-5). Here, we describe the nCoVega COVID-19 antigen rapid test (~ 15min) that can detect the presence of the SARS-COV-2 virus particles from saliva sample on a portable device. The portable reader instrument, the Vega-200, has a small footprint and is designed for use at point of care settings. The test detects the fluorescence signal using wide-field illumination from antigen-antibody complexes captured on a special filter matrix (6). Results of this clinical evaluation of 183 subjects demonstrates that the nCoVega COVID-19 test performs at par with qRT-PCR tests (7) (gold standard) for both symptomatic and asymptomatic patients, with a strong inverse correlation between RFU (relative fluorescence units) and Ct counts (from RT-PCR) maintaining detection accuracy even at very low viral loads. The test has an analytical performance of 15.3 TCID50/mL, and 100% specificity for COVID-19 as compared to other human respiratory viruses, including other human coronaviruses. The working principle of this assay and test system can be used for developing other rapid, inexpensive antigen assays and it can offer an end-to-end, point-of-care solution to meet the continuous demand in tackling existing and emerging infectious diseases across the globe.

Keywords: Point of care; immuno-fluorescence, COVID-19; SARS-COV-2; antigen, saliva.

1. Introduction 25

The nCoVega COVID-19 Antigen test, developed by Kaya 17, Inc., is an antigen-capture assay intended for the qualitative detection of spike protein antigen from SARS-CoV-2 in saliva from individuals, as viral antigen is generally detectable in saliva during the acute phase of infection. Positive results indicate the presence of viral antigens. This antigen test can be performed by trained non-laboratory or laboratory technicians for point of care use or for general use in clinical labs and hospital settings. The test works on a simple portable instrument called Vega-200 using a custom cartridge, assay reagents, and Vega software. The workflow uses a QR code reader and printer for tracking patient information.

The vast majority of COVID-19 antigen tests utilize lateral flow technology, which has inherent limitations in terms of dynamic range, sensitivity and specificity (8-10). The current rapid antigen tests are approved for nasal or NP swab. Other approaches include magnetic force assisted ELISA, microfluidic ELISA and digital chromatographic immunoassays, all of which require costly and complex custom manufacturing.

The nCoVega test utilizes selective antigen-antibody complex capture via filtration on an inexpensive and easy to manufacture disposable cartridge, and wide-field fluorescence imaging designed to give results in a few minutes with very high sensitivity and specificity. The reader is designed to run on USB power and is portable, light with no moving parts. Test format is designed so that 30-50 tests per hour can be processed on one reader. The workflow for our end-to-end solution including the test and the system is shown below in NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. figure 1.

The novel nCoVega COVID19 Antigen test is a direct dual probe antigen capture test using two fluorescently labeled primary antibodies (S1 and S2 spike protein recombinant IgG) that bind to SARS-CoV-2 spike protein on viral particles present in a saliva sample.

The developed test therefore can be easily deployed for large-scale population testing under community health settings, hospitals, and at the point of care with minimal operator training. This rapid and inexpensive test could help with COVID-19 diagnosis and controlling the spread of the global pandemic. The test can also be used to support decisions on infection control strategies such as detecting and isolating asymptomatic cases that could spread the virus unknowingly.

End to End Solution for COVID testing with Kaya17 Vega App




Figure 1: Schematic diagram showing the workflow for the nCoVega Test on the Vega-200 platform

The study described here investigates the overall accuracy and sensitivity of the nCoVega antigen test in comparison with a high sensitivity RT-PCR method as the gold standard (7) for diagnosis of COVID-19.

2. Materials and Methods

Sample collection and processing: A saliva sample (approximately 200ul) is collected at the point of care testing by directly spitting into a vial that is placed in a syringe fitted with a filter. 1 mL of the proprietary sample processing reagent is added. A plunger is pushed to allow the treated saliva sample to pass through the filter and is collected in a second tube for antibody labeling. The filtrate is incubated with 30ul of fluorescently-labeled S1 and S2 antibodies for 10 minutes at room temperature. The mixture is then passed through a disposable vertical flow cartridge fitted with a proprietary capture matrix. The fluorescence signal from the captured antigen-antibody complex is recorded using a portable device equipped with wide-field illumination.

Antibodies and conjugation: The S1 and S2 antibodies used in our test are purchased from GeneTex, TX and conjugated with a Biotium Mix-n-Stain CF 405L fluorophore (Biotium Inc, Fremont, CA, USA). The fluorophore used in our test has a large Stokes Shift with an excitation peak at 395nm and emission peak

around 545 nm. S1 and S2 antibodies are conjugated using the Mix-n-Stain protocol following the manufacturer's protocol, which consists of direct labeling of the antibodies to the fluorophore via an NHS-ester covalent bond formation. The conjugated antibodies are then purified via spin column centrifugation and buffer exchanged into a PBS-based storage buffer. The CF dyes were carefully chosen for their superior brightness, photostability, large Stokes Shift, and resistance to hydrolysis offering superior performance over most dyes.

Instrument and data collection: The patient saliva sample labeled with fluorescent antibodies is placed on the cartridge inside a well, lined at the bottom with a capture matrix. An absorbent pad inside the cartridge holder to remove excess liquid and the unbound antibody. The bound antibody/antigen complex is selectively retained on the capture matrix via size exclusion mechanism. 500ul of wash reagent is added to the cartridge and allowed to wick through. Finally, 500ul of proprietary read reagent is added to the cartridge and the cartridge is immediately placed on the Vega-200 instrument for readout. The Vega-200 instrument records the fluorescence from the captured complex on the cartridge and reports a qualitative result (Positive or Negative). The system portable Vega-200 instrument is a fluorescence reader (U.S. Patent Application Serial Number: 16/690,589). The Vega analysis software, Patient ID software, an ID scanner with a QR code printer were all run on a standard PC. In addition, data reporting via a mobile device is also available.

Data availability 87

Detailed data directly used to generate each figure or table of this study are available within the article, Supplementary Information and source data are also provided with this paper.

Method used to determine LoD:

Concentrations ranging from 1.6 x 105 TCID50/mL to 1.0 x 101 TCID50/mL Heat killed Zeptometrix SARS-CoV-2 (Cat. No. 0810587CFHI Lot No.324930) was spiked into artificial saliva matrix from Pickering laboratory (1700-0316).

Limit of Detection (LoD) for Kaya17 nCoVega test was determined by performing serial dilution (Table 1). A 10-fold serial dilution of was performed from 10,000, 1,000, 100, 10 and 0 of Heat Killed SARS CoV 2 from Zeptometrix in triplicate in Artificial saliva matrix from Pickering laboratory (1700-0316) (Figure 2a). From this, the LoD was estimated as 15.3 TCID50 per ml by Probit analysis (Figure 2b). Raw data is included in the supplementary material section (Table 1, supplementary materials section).

Cross reactivity (analytical specificity):

Each organism was tested in the absence or presence of Heat Killed SARS-CoV-2 from Zeptometrix at $3 \times LoD$ in Artificial saliva matrix from Pickering laboratory (1700-0316). The final concentration of the organisms is in the Table 3 below (the concentrations of 106 CFU/mL or higher for bacteria and 105 PFU/mL or higher for viruses is recommended). For some of the microorganisms, the stock concentration was lower than or equal to the recommended testing concentration. In such cases, these microorganisms were used at the stock concentration.

Microbial Interference Studies:

Each organism was tested in the absence or presence of Heat Killed SARS-CoV-2 from Zeptometrix at 3 x LoD in Artificial saliva matrix from Pickering laboratory (1700-0316). The final concentration of the organisms is in the Table 4 below (the concentrations of 10^6 CFU/mL or higher for bacteria and 10^5 PFU/mL or higher for viruses is recommended). For some of the microorganisms, the stock concentration was lower than or equal to the recommended testing concentration. In such cases, these microorganisms were used at the stock concentration.

Endogenous Interference Studies

Each substance was tested in triplicate in the absence or presence of Heat Killed SARS-CoV-2 from Zeptometrix at 3 x LOD in Artificial saliva matrix from Pickering laboratory (1700-0316). Substances for testing were selected based on the respiratory specimen's guidance in http://www.accessdata.fda.gov/cdrh_docs/reviews/K112177.pdf.

Hook Effect Testing:

To determine if the Kaya17 nCoVega Test suffers from any high dose Hook effect, increasing concentrations of Heat Killed SARS-CoV-2 from Zeptometrix at 3 x LoD, were tested up to a concentration of 1.6 x 105 TCID50/mL. The starting material was spiked into a pooled negative saliva matrix obtained from healthy donors and confirmed negative for SARS-CoV-2. At each dilution, 500μ L samples were added to Extraction buffer and tested using the nCoVega test.

Clinical Evaluation 126

A prospective, single center, comparative study for validation of a rapid point-of-care test for diagnosis of SARS-COV-2 infection was conducted to evaluate the clinical use of the Kaya17 nCoVega COVID-19 Antigen test for use with saliva specimens collected neat.

The Kaya17 nCoVega COVID-19 Antigen test was clinically validated by Infinity BiologiX (IBX) using 183 paired saliva and swab samples (79 positives and 104 negatives) collected by St. Rose Hospital, Hayward, CA as per KAYA-PROTOPOCT-007 Prospective Clinical Study Protocol. The Western IRB approval number for the clinical trial was IRB protocol #20204097. Informed consents were collected from each subject along with basic medical history. The samples utilized in the study were analyzed using an RT PCR assay (Control), PerkinElmer New Coronavirus Nucleic Acid Detection Kit.

The primary objective of the study was to demonstrate efficacy of the Kaya17 nCoVega COVID-19 Antigen test in a non-laboratory setting by verifying the sensitivity and specificity of the Kaya17 nCoVega COVID-19 Antigen test in detecting SARS-COV-2 in positive saliva samples (yields a "positive" result) and not detecting SARS-COV-2 in negative saliva samples (yields a "negative" result) when performed by non-laboratory personnel. The secondary objective in the same protocol was to demonstrate that non-laboratory healthcare providers can perform the Kaya17 nCoVega COVID-19 Antigen test accurately in the intended use environment to Support Point of Care (POC) Use. (Point of Care study). In addition, the accuracy of detection was assessed in asymptomatic and symptomatic patients from day 1 of symptoms.

The data generated from the clinical study were statistically analyzed as per the following techniques

- Positive percent agreement (PPA),
- Negative percent agreement (NPA),
- Overall percent agreement (OPA),
- Associated 95% Wilson score confidence intervals
- Concordance analysis of the Kaya17 nCoVega Antigen test RFU vs Ct values of PCR

Subject status (negative/positive) was determined using a receiver operating characteristic (ROC) curve cutoff analysis. The evaluation metrics included positive percent agreement (PPA), negative percent agreement (NPA), overall percent agreement (OPA), and the absolute value of the sensitivity minus the specificity.

Before testing any of the samples, sample cartridges with positive and negative controls were inserted on the Vega 200 instrument that recorded fluorescence from these samples in RFU. This allowed the Vega analysis software to decide the cut-off value to use when deciding on positive and negative COVID-19 calls for sample testing. Details of the result interpretation are cited below in their respective sections. Raw data for the plots are also included in the supplementary information section.

All test controls were examined prior to interpretation of results. If the controls were not valid, the samples were not analyzed using the kit/instrument. Additional kits or instruments are required to be validated prior to running samples. The test result was determined by cutoff values based on fluorescence measurements on the Vega-200 instrument (excitation at 395 nm and emission at 545 nm). A "POSITIVE" result is called by the Vega software if the fluorescence measurement of the sample is above baseline fluorescence that has been determined by running the negative control multiple times. If the fluorescence value is at or below baseline, a "NEGATIVE" result is called by the Vega software. The results are stored in a CSV file on the Vega Reader computer. Further details are provided in the supplementary section.

3. Results 168

For laboratory validation of the nCoVega COVID19 Antigen test, a number of different studies were conducted such as analytical performance testing, LOD, cross-reactivity, inclusion and exclusion panel testing and hook effect testing. The details of each of those tests served to establish the sensitivity and specificity of the assay and the results are presented below.

3.1. Analytical Performance

3.1.1. Limit of Detection (LoD) Determination

LoD studies were performed to determine the lowest detectable concentration of SARS-CoV-2 at which approximately 95% of all (true positive) replicates test positive.




Figure 2 (a): LoD determination and dynamic range based on data from Table 1 (see supplementary section)

From the ten-fold dilution series results in Table 1, the LoD can be determined as at least 10 TCID50/mL, since all samples with concentrations from 100000 TCID50/mL down to 10 TCID50/mL were above the 0 TCID50/mL. At 10 TCID50/mL, one of the replicates showed negative result (0.299 (S6)). Hence the LoD was set at 20 TCID50/mL. Probit analysis not possible due to 100% assessment of positivity at all positive concentration levels.

The ability to detect SARS-CoV-2 with Kaya17 nCoVega test at 20 TCID $_{50}$ per ml was further confirmed by testing 20 replicates (Table 1a in supplementary section).

Limit of Blank (LoB) experiments were performed by running 20 samples at 0 TCID50 per ml LOB (Table 1a in supplementary section).

3.1.2 Assay Cutoff Determination

Determining the assay cutoff was a key part of the data analysis. The assay cutoff determination for positives and negatives is determined using the Currie's method (11) and CLSI EP17 guidance (12) for our qualitative purposes as follows.

From the guidance, the LoB' is defined as:

$$LoB' = MB + Cp \bullet SDB$$

where M refers to the mean of "blank" samples and Cp is the multiplier and SDB is the Standard Deviation of the Blank Samples. As the data are very precise, in this case using a two-sided 5% significance level, Cp is defined as

$$Cp = \frac{1.96}{1 - \left(\frac{1}{4(B - K)}\right)} \qquad Cp = 1.96/(1 - (1/4(B - K)))$$

where B is the total number of blank replicates and K is the number of blank samples.

Therefore, from the data in the spreadsheet (see supplementary section), the LOB' is calculated as:

$$LoB' = 0.9311 + 1.9861 \cdot 0.0027 = 0.9364$$
 or 0.936.

Next, per the guidance, the LOD' can be calculated as:

$$LoD' = LoB' + Cp \bullet SDL = 0.9364 + 1.9861 \bullet 0.00266 = 0.94168 \text{ or } 0.942.$$

where
$$Cp = 1.96/[1-(1/4 \bullet (Nreplicates - Nsamples))] = 1.96/[1-(1/4 \bullet (20-1))] = 1.9861$$
.

and SDL = 0.00266 is the standard deviation of the positive low concentration samples with appropriate provision for degrees of freedom depending on the number of samples used to obtain the total replicates.

Therefore, if the LoB' is taken as the cutoff (11), then we can establish a conservative equivocal zone between the LoB' and the LoD' as between 0.936 and 0.942 mean RR with the actual cutoff as 0.939 (as determined by ROC curve methodology in clinical evaluation (12)). Therefore, if a patient were to test in this equivocal

7 of 33 zone, their result should be assigned as 'Indeterminate' and a retest is performed. 212 213 3.1.3 Cross-reactivity (Analytical Specificity) 214 We performed cross-reactivity studies for Kaya17 nCoVega test using a panel of related pathogens, normal or 215 pathogenic flora that are reasonably found in the clinical specimen. Also, the high prevalence disease agents 216 likely to be encountered in the clinical specimen were tested for specificity of the test and the results showed 217 no potential cross-reactivity with the Kaya17 nCoVega test with these agents, including various 218 microorganisms and pathogens. 219

Table 3: Results of Cross-reactivity study.

220

222

223

224

225

Microorganism	Source	Concentration	Cross-Reactivity (Yes/No)
Human coronavirus 229E	Zeptometrix	1 x 10 ⁵ TCID ₅₀ /mL	No (3/3 negative)
Human coronavirus OC43	Zeptometrix	1 x 10 ⁵ TCID ₅₀ /mL	No (3/3 Negative)
Human coronavirus NL63	Zeptometrix	1 x 10 ⁵ TCID ₅₀ /mL	No (3/3 Negative)
MERS coronavirus	Zeptometrix	1 x 10 ⁵ TCID ₅₀ /mL	No (3/3 Negative)
Adenovirus	Zeptometrix	1 x 10 ⁵ TCID ₅₀ /mL	No (3/3 Negative)
Human Metapneumovirus (hMPV)	Zeptometrix	1 x 10 ⁵ TCID ₅₀ /mL	No (3/3 Negative)
Parainfluenza virus Type 1	Zeptometrix	1 x 10 ⁵ TCID ₅₀ /mL	No (3/3 Negative)
Parainfluenza virus Type 2	Zeptometrix	1 x 10 ⁵ TCID ₅₀ /mL	No (3/3 Negative)
Parainfluenza virus Type 3	Zeptometrix	1 x 10 ⁵ TCID ₅₀ /mL	No (3/3 Negative)
Parainfluenza virus Type 4a	Zeptometrix	1 x 10 ⁵ TCID ₅₀ /mL	No (3/3 Negative)
Influenza A H3N2 (Wisconsin/67/05)	BEI Resources	5.4 x 10 ⁴ TCID ₅₀ /mL	No (3/3 Negative)
Influenza A H1N1	Zeptometrix	1 x 10 ⁵ TCID ₅₀ /mL	No (3/3 Negative)
Influenza B (Florida/02/06)	Zeptometrix	1 x 10 ⁵ TCID ₅₀ /mL	No (3/3 Negative)
Enterovirus Type 68	Zeptometrix	1 x 10 ⁵ TCID ₅₀ /mL	No (3/3 Negative)
Respiratory syncytial Virus Type B	Zeptometrix	1 x 10 ⁵ TCID ₅₀ /mL	No (3/3 Negative)
Rhinovirus	Zeptometrix	1 x 10 ⁵ TCID ₅₀ /mL	No (3/3 Negative)
SARS-CoV	BEI Resources	1x10 ⁵ PFU/mL	No (3/3 Negative)
Herpes Simplex Virus	Zeptometrix	1 x 10 ⁵ TCID ₅₀ /mL	No (3/3 Negative)
Epstein Barr Virus	Zeptometrix	1.03x10 ³ cp/mL	No (3/3 Negative)
Haemophilus influenzae	Zeptometrix	1 x 10 ⁶ CFU/mL	No (3/3 Negative)
Streptococcus pneumoniae	Zeptometrix	1 x 10 ⁶ CFU/mL	No (3/3 Negative)
Streptococcus pyogenes	Zeptometrix	1 x 10 ⁶ CFU/mL	No (3/3 Negative)
Candida albicans	Zeptometrix	1 x 10 ⁶ CFU/mL	No (3/3 Negative)
Bordetella pertussis	Zeptometrix	1 x 10 ⁶ CFU/mL	No (3/3 Negative)
Chlamydophila pneumoniae	Zeptometrix	1 x 10 ⁶ CFU/mL	No (3/3 Negative)
Legionella pneumophila	Zeptometrix	1 x 10 ⁶ CFU/mL	No (3/3 Negative)
Mycobacterium tuberculosis	Zeptometrix	1 x 10 ⁶ CFU/mL	No (3/3 Negative)
Pneumocystis jirovecii	Zeptometrix	1 x 10 ⁶ CFU/mL	No (3/3 Negative)
Pseudomonas Aeruginosa	Zeptometrix	1 x 10 ⁶ CFU/mL	No (3/3 Negative)
Staphylococcus Epidermidis	Zeptometrix	1 x 10 ⁶ CFU/mL	No (3/3 Negative)
Streptococcus Salivarius	Zeptometrix	1 x 10 ⁶ CFU/mL	No (3/3 Negative)
Mycoplasma pneumoniae	Zeptometrix	1 x 10 ⁶ CFU/mL	No (3/3 Negative)
Pooled human Kaya17 nasal wash	Kaya17	14% v/v	No (3/3 Negative)
Elkenella corrodens	Zeptometrix	1 x 10 ⁶ CFU/mL	No (3/3 Negative)
Streptococcus mutans	Zeptometrix	1 x 10 ⁶ CFU/mL	No (3/3 Negative)
Staphlocccus aureus	Zeptometrix	1 x 10 ⁶ CFU/mL	No (3/3 Negative)
Neisseria Meningitidis	Zeptometrix	1 x 10 ⁶ CFU/mL	No (3/3 Negative)
Nocardia asteriods	Zeptometrix	1 x 10 ⁶ CFU/mL	No (3/3 Negative)
Moraxella catarrhalis	Zeptometrix	1 x 10 ⁶ CFU/mL	No (3/3 Negative)
Streptococcus mitis	Zeptometrix	1 x 10 ⁶ CFU/mL	No (3/3 Negative)

3.1.4. Microbial Interference Studies

Microbial Interference for Kaya17 nCoVega test was evaluated by using a panel of related pathogens, normal or pathogenic flora that are reasonably found in the clinical specimen. Also, high prevalence disease agents

226

227

228

were tested for specificity to demonstrate that false negatives do not occur when SARS-CoV-2 is present in a specimen with other microorganisms.

Table 4: Results of Microbial Interference studies

Microorganism	Source	Concentration	Interference (Yes/No)
Human coronavirus 229E	Zeptometrix	1 x 10 ⁵ TCID ₅₀ /mL	No (3/3 positive)
Human coronavirus OC43	Zeptometrix	1 x 10 ⁵ TCID ₅₀ /mL	No (3/3 positive)
Human coronavirus NL63	Zeptometrix	1 x 10 ⁵ TCID ₅₀ /mL	No (3/3 positive)
MERS coronavirus	Zeptometrix	1 x 10 ⁵ TCID ₅₀ /mL	No (3/3 positive)
Adenovirus	Zeptometrix	1 x 10 ⁵ TCID ₅₀ /mL	No (3/3 positive)
Human Metapneumovirus (hMPV)	Zeptometrix	1 x 10 ⁵ TCID ₅₀ /mL	No (3/3 positive)
Parainfluenza virus Type 1	Zeptometrix	1 x 10 ⁵ TCID ₅₀ /mL	No (3/3 positive)
Parainfluenza virus Type 2	Zeptometrix	1 x 10 ⁵ TCID ₅₀ /mL	No (3/3 positive)
Parainfluenza virus Type 3	Zeptometrix	1 x 10 ⁵ TCID ₅₀ /mL	No (3/3 positive)
Parainfluenza virus Type 4a	Zeptometrix	1 x 10 ⁵ TCID ₅₀ /mL	No (3/3 positive)
Influenza A H3N2 (Wisconsin/67/05)	BEI Resources	5.4 x 10 ⁴ TCID ₅₀ /mL	No (3/3 positive)
Influenza A H1N1	Zeptometrix	1 x 10 ⁵ TCID ₅₀ /mL	No (3/3 positive)
Influenza B (Florida/02/06)	Zeptometrix	1 x 10 ⁵ TCID ₅₀ /mL	No (3/3 positive)
Enterovirus Type 68	Zeptometrix	1 x 10 ⁵ TCID ₅₀ /mL	No (3/3 positive)
Respiratory syncytial Virus Type B	Zeptometrix	1 x 10 ⁵ TCID ₅₀ /mL	No (3/3 positive)
Rhinovirus	Zeptometrix	1 x 10 ⁵ TCID ₅₀ /mL	No (3/3 positive)
SARS-CoV	BEI Resources	1x10 ⁵ PFU/mL	No (3/3 positive)
Herpes Simplex Virus	Zeptometrix	1 x 10 ⁵ TCID ₅₀ /mL	No (3/3 positive)
Epstein Barr Virus	Zeptometrix	1.03x10 ³ cp/mL	No (3/3 positive)
Haemophilus influenzae	Zeptometrix	1 x 10 ⁶ CFU/mL	No (3/3 positive)
Streptococcus pneumoniae	Zeptometrix	1 x 10 ⁶ CFU/mL	No (3/3 positive)

Streptococcus pyogenes	Zeptometrix	1 x 10 ⁶ CFU/mL	No (3/3 positive)
Candida albicans	Zeptometrix	1 x 10 ⁶ CFU/mL	No (3/3 positive)
Bordetella pertussis	Zeptometrix	1 x 10 ⁶ CFU/mL	No (3/3 positive)
Chlamydophila pneumoniae	Zeptometrix	1 x 10 ⁶ CFU/mL	No (3/3 positive)
Legionella pneumophila	Zeptometrix	1 x 10 ⁶ CFU/mL	No (3/3 positive)
Mycobacterium tuberculosis	Zeptometrix	1 x 10 ⁶ CFU/mL	No (3/3 positive)
Pneumocystis jirovecii	Zeptometrix	1 x 10 ⁶ CFU/mL	No (3/3 positive)
Pseudomonas Aeruginosa	Zeptometrix	1 x 10 ⁶ CFU/mL	No (3/3 positive)
Staphylococcus Epidermidis	Zeptometrix	1 x 10 ⁶ CFU/mL	No (3/3 positive)
Streptococcus Salivarius	Zeptometrix	1 x 10 ⁶ CFU/mL	No (3/3 positive)
Mycoplasma pneumoniae	Zeptometrix	1 x 10 ⁶ CFU/mL	No (3/3 positive)
Pooled human Kaya17 nasal wash	Kaya17	14% v/v	No (3/3 positive)
Elkenella corrodens	Zeptometrix	1 x 10 ⁶ CFU/mL	No (3/3 positive)
Streptococcus mutans	Zeptometrix	1 x 10 ⁶ CFU/mL	No (3/3 positive)
Staphlocccus aureus	Zeptometrix	1 x 10 ⁶ CFU/mL	No (3/3 positive)
Neisseria Meningitidis	Zeptometrix	1 x 10 ⁶ CFU/mL	No (3/3 positive)
Nocardia asteriods	Zeptometrix	1 x 10 ⁶ CFU/mL	No (3/3 positive)
Moraxella catarrhalis	Zeptometrix	1 x 10 ⁶ CFU/mL	No (3/3 positive)
Streptococcus mitis	Zeptometrix	1 x 10 ⁶ CFU/mL	No (3/3 positive)

3.1.5. Endogenous Interference Substances Studies

The following study was conducted to investigate whether potentially interfering substances, which may be found in the mouth and throat of symptomatic subjects (including over-the-counter medications), cross-react or interfere with the detection of SARS-CoV-2 using the Kaya17 nCoVega test. There was no interference with any of the tested materials in the study as described in Table 5.

Table 5: Results of Interference Studies

Interfering Substance	Concentration	Interference (Yes/No)
		No
		(3/3 Negative, 3/3 Positive)
Clarispray	50mcg	,
		No
		(3/3 Negative, 3/3 Positive)
Blood (human)	5%	
		No
		(3/3 Negative, 3/3 Positive)
Mucin	5 mg/mL	
		No
		(3/3 Negative, 3/3 Positive)
Fluticasone Propionate Flovant HFA	110mcg	
		No
		(3/3 Negative, 3/3 Positive)
Ventolin HFA Albuterol	90mcg	
		No
		(3/3 Negative, 3/3 Positive)
Budesonide and Fromoterol Fumarate Dihydrate	80mcg/4.5mcg	
		No
		(3/3 Negative, 3/3 Positive)
Anefrin oxymetazoline HCI	0.05% v/v	
•		No
		(3/3 Negative, 3/3 Positive)
Azelastine HCI	137mcg	
		No
		(3/3 Negative, 3/3 Positive)
Sore Throat Phenol Spray	15% v/v	
, ,		No
		(3/3 Negative, 3/3 Positive)
Montelukast (Singular)	0.5mg	
, ,		No
		(3/3 Negative, 3/3 Positive)
Laratadine (Claritin)	0.15 mg/dL	
,		No
		(3/3 Negative, 3/3 Positive)
Human Genomic DNA	10 ug.mL	(3,000)
Transfer Continue Divi	10 ag.mz	No
Nyavil (Acataminanhan, Davidemina avesis sta		(3/3 Negative, 3/3 Positive)
Nyquil (Acetaminophen, Doxylamine succinate,	2 100 11	(5.5 Negative, 5.5 Festive)
Dextromethorphan HBr)	2 mg/mL	Ne
		No
Taathaasta (Calaata)	0.50//-	(3/3 Negative, 3/3 Positive)
Toothpaste (Colgate)	0.5% v/v	

		No
Crest/Listerine Mouthwash (Eucalyptol, menthol,		(3/3 Negative, 3/3 Positive)
Methyl Salicylate, Thymol)	5% v/v	
		No
		(3/3 Negative, 3/3 Positive)
Zinc	10mg/mL	,
	· ·	No
		(3/3 Negative, 3/3 Positive)
Emergen-C	10mg/mL	, , , , , , , , , , , , , , , , , , , ,
		No
		(3/3 Negative, 3/3 Positive)
Chloraseptic (Menthol/Benzocaine)	1.5 mg/mL	,
	Ĭ.	No
		(3/3 Negative, 3/3 Positive)
CVS Nasal Drops (Phenylephrine)	15% v/v	,
		No
		(3/3 Negative, 3/3 Positive)
Afrin (Oxymetazoline)	15% v/v	
		No
		(3/3 Negative, 3/3 Positive)
CVS Nasal Spray (Cromolyn)	15% v/v	,
		No
		(3/3 Negative, 3/3 Positive)
Zicam	5% v/v	, , , , , , , , , , , , , , , , , , , ,
	277	No
		(3/3 Negative, 3/3 Positive)
Homeopathic (Alkalol)	1:10 Dilution	(orangame, are reaming)
, , , , , , , , , , , , , , , , , , , ,		No
		(3/3 Negative, 3/3 Positive)
Sore Throat Phenol Spray	15% v/v	
, ,		No
		(3/3 Negative, 3/3 Positive)
Robitussin	2 mg/mL	
		No
		(3/3 Negative, 3/3 Positive)
Alcohol (Ethanol)	5%	
		No
		(3/3 Negative, 3/3 Positive)
Nicotine	0.03 mg/mL	, , , , , , , , , , , , , , , , , , , ,
	, in the second	No
		(3/3 Negative, 3/3 Positive)
Vaseline (Petroleum Jelly)	15% v/v	, , , , , , , , , , , , , , , , , , , ,
, , , , , , , , , , , , , , , , , , , ,		No
		(3/3 Negative, 3/3 Positive)
Tamiflu (Oseltamivir Phosphate)	5mg/mL	,
		No
Tobacco (Nicotine, Tar, Carbon Monoxide,		(3/3 Negative, 3/3 Positive)
Formaldehyde, Ammonia, Hydrogen Cyanide,		,,,
Arsenic, and DDT)	0.05mg/mL	

3.2 <u>High-dose Hook Effect:</u>

The Weibull statistical model was used for the data analysis (x axis=log10 $TCID_{50}$ copies; y axis =Raw Average). The analysis showed that at the top end of the assay (1.6 x 10^5 $TCID_{50}$ copies) there is a plateau. This provides evidence that a Hook effect does not exist for this assay up to 1.6×10^5 $TCID_{50}$ copies. The model fits, as measured by the correlation and coefficient of determination, were each about 0.99 (closer to 1.00 is desired). Specific model information is shown in the figure 3.

249

250

251

253

254

255

256

257

258

259260

262

263

264

265266267268269

261

Overview

 Name
 Weibull Model

 Kind
 Regression

 Family
 Sigmoidal Models

 Equation
 y = a - b*exp(-c*x*d)

 # of Indep. Vars
 1

 Weighting
 Default

 Standard Error
 0.022830668235798594

 Correlation Coeff. (r)
 0.994782

 Coeff. of Determination (r*2)
 0.989591573703048

 DOF
 17

 AICC
 -155.771049

Parameters

	Value	Std Err	Range (95% confidence)
а	1.440984	0.013098	1.413350 to 1.468618
b	0.486479	0.015155	0.454504 to 0.518453
C	0.000000	0.000000	-0.000000 to 0.000000
d	11.748741	1.621902	8.326827 to 15.170655




Figure 3. Weibull statistical analysis of Hook effect data

3.3 Clinical Evaluation: 252

A total of n=183 samples were collected during the clinical evaluation. A total of n=183 test samples utilizing the subject device resulted in the same result (i.e., positive or negative) in comparison to the control, except two (n=2) test sample rendered a positive result when using the subject device and a negative result when using the control. One (n=1) test samples rendered a negative result when using the subject device and a positive result when using the control. After conducting statistical analysis, a 98.4% degree of accuracy is established based on the data set (Table 6).

Accuracy in Overall Patient Population

The test results include 79 True Positives (RT-PCR Positives) and 104 True negatives (RT-PCR Negatives) (data in Table 2 in supplemental materials). When we analyzed the performance of the Kaya17 assay in overall population, the PPA value is calculated to be 98.7% and at 95% Confidence Interval, values are found to be at (93.2% Lower bound, 99.8% Upper bound).

276

277

278

279

280281

283

284

285

Table 6: Accuracy in Overall Patient Population

		PCR 1	Reference Re	esult		Agreement	
Comparator Assay	Test Result	Positive	Negative	Total	Measure [a]	% (n/N)	95% CI [b]
	Positive	78	2	80	PPA	98.7 (78/79)	(93.2, 99.8)
Kaya17 (Overall)	Negative	1	102	103	NPA	98.1 (102/104)	(93.3, 99.5)
	Total	79	104	183	ОРА	98.4 (180/183)	(95.3, 99.4)

[[]a] PPA=Positive Percent Agreement, NPA=Negative Percent Agreement, OPA=Overall Percent Agreement.

Accuracy in Symptomatic Patient Population

In the Symptomatic population (Table 7), there are 73 RT-PCR positives (True Positives) and 45 RT-PCR negatives (True Negatives). When we analyzed the performance of the Kaya17 assay in symptomatic population, the PPA value is calculated to be 98.6% and at 95% Confidence Interval, values are found to be at (92.60% Lower bound, 99.8% Upper bound).

Table 7: Accuracy in Symptomatic Patient Population

		PCR Reference Result			Agreement		
Comparator Assay	Test Result	Positive	Negative	Total	Measure [a]	% (n/N)	95% CI [b]
	Positive	72	1	73	PPA	98.6 (72/73)	(92.6, 99.8)
Kaya17 (Symptomatic)	Negative	1	44	45	NPA	97.8 (44/45)	(88.4, 99.6)
	Total	73	45	118	OPA	98.3 (116/118)	(94.0, 99.5)

[[]a] PPA=Positive Percent Agreement, NPA=Negative Percent Agreement, OPA=Overall Percent Agreement.

As seen in the raw data in Table 2 in the supplementary section, the nCovega test was able to detect the SARS-COV-2 virus as early as day 1 from the onset of smptoms.

[[]b] Wilson Score Confidence Interval.

[[]b] Wilson Score Confidence Interval.

Accuracy in Asymptomatic Patient Population

In the Asymptomatic population (Table 8), there are 6 RT-PCR positives (True Positives) and 59 RT-PCR negatives (True Negatives). When we analyzed the performance of the Kaya17 assay in asymptomatic population, the PPA value is calculated to be 100% and at 95% *Confidence Interval*, values are found to be at (61% Lower bound, 100% Upper bound).

Table 8: Accuracy in Asymptomatic Patient Population

		PCR Reference Result		Agreement			
Comparator Assay	Test Result	Positive	Negative	Total	Measure [a]	% (n/N)	95% CI [b]
	Positive	6	1	7	PPA	100.0 (6/6)	(61.0, 100.0)
Kaya17 (Asymptomatic)	Negative	0	58	58	NPA	98.3 (58/59)	(91.0, 99.7)
	Total	6	59	65	OPA	98.5 (64/65)	(91.8, 99.7)

[[]a] PPA=Positive Percent Agreement, NPA=Negative Percent Agreement, OPA=Overall Percent Agreement.

The operator specific accuracy is measured to support the POC Study to demonstrate that the Kaya17 nCoVega COVID-19 Antigen test can be performed by the untrained operator following the Quick Reference Guide without any training. Each untrained operator has achieved the 95% accuracy. Please refer to the Table 9.

Table 9: Test results for each untrained operator.

S.No	Operator	Total No. Samples Tested	Correctly measured w.r.t Control	Accuracy (%)
1	Operator 1	41	39	95.1
2	Operator 2	36	36	100
3	Operator 3	39	39	100
4	Operator 4	43	42	97.7
5	Operator 5	54	54	100

It is also observed that there is no reader instrument variability while interpreting the results when the samples are tested. All the RT-PCR comparative results correlate with the Kaya17 results when 5 different reader instruments were used for testing by 5 different untrained operators.

[[]b] Wilson Score Confidence Interval.




Figure 4: Inverse Relationship between Kaya17 RFUs vs Ct values from RT-PCR

Figure 4 shows the inverse linear relationship between the observed Kaya17 RFUs versus the mean values of the N and ORF1ab Gene cycle thresholds (n=183, Pearson Correlation= -0.92). The figure shows that all of the negative samples by PCR were also Negative in Kaya17 nCoVega test, except for two samples (Sample Number 31and 117), all positive samples by PCR were also positive by Kaya17 nCoVega test, except for one sample (Sample Number 10).

Discussion:

The Kaya17 Vega-200 system and nCoVega antigen test is a simple-to-use, rapid assay that is also highly sensitive and specific. The test can detect very low levels of SARS-CoV-2 as seen in the high correlation with RT-PCR across all ranges of viral loads, all the way down to Ct counts of 38. The test also confirmed its capability to detect infected people as early as Day 1 from the start of symptoms. The reader instrument is light, portable and runs off USB-power from its connected laptop, so it does not need external power source. The system can also process 30-50 samples in one hour and can be run by untrained operators, making it a very useful test to apply at point of care sites for accurate detection of infected people very early before they spread the virus to others. The low LOD of 20 TCID₅₀/ml validates a sensitivity that is simmilar to RT-PCR (7) and several orders of magnitude more accurate/sensitive than most other antigen tests (13). A test like this with PCR-like sensitivity

and accuracy has significant implications in surveillance and population control, especially given its use of small volume of saliva sample which is very easy and non-invasive for all ages of subjects. The software, instrument and disposables including cartridge, provide an end-to-end solution that can be deployed in mobile units, at schools, offices and events and also in remote areas, given the instrument's small footprint and portability. Easily scalable manufacturing processes allow this test to meet any surge in demand for COVID-19 testing, as we open our schools, businesses and global travel and as new variants emerge. In the future, this test system can be productized for self-testing purposes. The nCoVega test can address the unmet need for rapid, accurate and inexpensive COVID-19 testing and it is suitable for broader public dissemination.

Cui J, Li F, Shi ZL. Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol. 2019, 17(3), 181-192.
 Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020, 579(7798), 270-273.
 Contini C, Di Nuzzo M, Barp N, et al. The novel zoonotic COVID-19 pandemic: An expected global health concern. J Infect Dev Ctries. 2020, 14(3), 254-264.
 Wu JT, Leung K, Bushman M, et al. Estimating clinical severity of COVID-19 from the transmission dynamics in 341

- . Kissler SM, Tedijanto C, Goldstein E, Grad YH, Lipsitch M. Projecting the transmission dynamics of SARS-CoV-2 through the postpandemic period [published online ahead of print, 2020 Apr 14]. Science. 2020; eabb5793.
- 6. Dwarakanath, S et al, Ultrasensitive Fluorescent Nanoparticle-Based Binding Assays for Foodborne and Waterborne Pathogens of Clinical Interest, J. of Clinical Ligand Assay, Fall 2006, Vol 29, No 3.
- 7. Altamimi, AM, Obeid, DA, Alaifan, TA, Taha, MT, Alhothali, MT, Alzahrani, FA, & Albarrag, AM. Assessment of 12 Qualitative RT-PCR commercial kits for the detection of SARS-CoV-2. Journal of medical virology, 2021, 10.1002 /jmv.26900
- 8. Eshghifar, N., Busheri, A., Shrestha, R., & Beqaj, S. Evaluation of Analytical Performance of Seven Rapid Antigen Detection Kits for Detection of SARS-CoV-2 Virus. International journal of general medicine, 2021, 14, 435–440.
- Mak GC, Lau SS, Wong KK, Chow NL, Lau CS, Lam ET, Chan RC, Tsang DN. Analytical sensitivity and clinical sensitivity of the three rapid antigen detection kits for detection of SARS-CoV-2 virus. J Clin Virol. 2020 Dec;133:104684
- 10. Kohmer N, Toptan T, Pallas C, et al. The Comparative Clinical Performance of Four SARS-CoV-2 Rapid Antigen Tests and Their Correlation to Infectivity In Vitro. J Clin Med. 2021, 10(2), 328.
- 11. Currie L (1968). Limits for qualitative detection and quantitative determination. Application to radiochemistry. Anal. Chem. 1968, 40, 3, 586–593.
- CLSI. Evaluation of Detection Capability for Clinical Laboratory Measurement Procedures; Approved Guideline— Second Edition. CLSI document EP17-A2. Wayne, PA: Clinical and Laboratory Standards Institute; 2012.
- 13. Weissleder R, Hakho L, Ko J, and Pittet M. COVID-19 diagnostics in context. Science Translational Medicine. 3 Jun 2020. Vol 12, Issue 54, p6.

Author Contributions: SD and VM conceived the study and cross-platform validation experiments at ASU. SS led the design and development of the Vega-200 system. SD, CBT, TC, AM, DM developed and optimized the nCoVega SARS-CoV-2 assay. DM and SD ran the analytical study. SD, CBT ran the clinical validation study at ASU. JC, JM and CBT analyzed the data. TC, SM and SD drafted the manuscript. CBT revised the manuscript. All authors read and approved the final manuscript.

Funding: This research received no external funding

Wuhan, China. Nat Med. 2020, 26(4):506-510.

Institutional Review Board Statement: The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Institutional Review Board (or Ethics Committee) of Western IRB (IRB protocol #20204097; Kaya17 protocol #KAYA-PROTOPOCT-007 Rev002) on 01/06/2021.

379 380 381

382 383

384

385

Supplementary Materials

Table 1: LOD LOB testing raw data

Operator: Arsh ReaderID: R6

ID	Bgd_Rdg	Thr_Rdg	Raw_Avg	Test_Results	Sample_Name
C1	-2.362	0.3	0.298	NEG	NEG Control
C2	-2.362	0.3	0.347	POS	POS control
S3	-2.362	0.3	0.337	POS	20
S4	-2.362	0.3	0.333	POS	20
S5	-2.362	0.3	0.336	POS	20
S6	-2.362	0.3	0.338	POS	20
S7	-2.362	0.3	0.331	POS	20
S8	-2.362	0.3	0.334	POS	20
S9	-2.362	0.3	0.333	POS	20
S10	-2.362	0.3	0.335	POS	20
S11	-2.362	0.3	0.334	POS	20
S12	-2.362	0.3	0.337	POS	20
S13	-2.362	0.3	0.338	POS	20
S14	-2.362	0.3	0.333	POS	20
S15	-2.362	0.3	0.338	POS	20
S16	-2.362	0.3	0.336	POS	20
S17	-2.362	0.3	0.335	POS	20
S18	-2.362	0.3	0.336	POS	20
S19	-2.362	0.3	0.331	POS	20
S20	-2.362	0.3	0.332	POS	20
S21	-2.362	0.3	0.331	POS	20
S22	-2.362	0.3	0.335	POS	20
S23	-2.362	0.3	0.3	NEG	0
S24	-2.362	0.3	0.3	NEG	0
S25	-2.362	0.3	0.299	NEG	0
S26	-2.362	0.3	0.3	NEG	0
S27	-2.362	0.3	0.3	NEG	0
S28	-2.362	0.3	0.299	NEG	0
S29	-2.362	0.3	0.3	NEG	0
S30	-2.362	0.3	0.298	NEG	0
S31	-2.362	0.3	0.3	NEG	0
S32	-2.362	0.3	0.3	NEG	0
S33	-2.362	0.3	0.3	NEG	0
S34	-2.362	0.3	0.298	NEG	0

20	of	33

S35	-2.362	0.3	0.3	NEG	0
S36	-2.362	0.3	0.3	NEG	0
S37	-2.362	0.3	0.3	NEG	0
S38	-2.362	0.3	0.3	NEG	0
S39	-2.362	0.3	0.3	NEG	0
S40	-2.362	0.3	0.297	NEG	0
S41	-2.362	0.3	0.3	NEG	0
S42	-2.362	0.3	0.299	NEG	0

TABLE 1a: Results of 20 replicates for LoD and LoB confirmation

ID	Raw Average	TCID ₅₀ /mL	
S3	0.337	20	SD of 20 TCID50/mL Samples
S4	0.333	20	0.00237
S5	0.336	20	
S6	0.338	20	
S7	0.331	20	Mean of LoD Samples:
S8	0.334	20	0.335
S9	0.333	20	
S10	0.335	20	
S11	0.334	20	
S12	0.337	20	
S13	0.338	20	
S14	0.333		
S15	0.338	20	
S16	0.336	20	
S17	0.335	20	
S18	0.336		
S19	0.331	20	
S20	0.332	20	
S21	0.331	20	
S22	0.335	20	
S23	0.3	0	Mean of Blank Samples:
S24	0.3	0	0.300
S25	0.299	0	
S26	0.3	0	SD of Blank Samples:
S27	0.3	0	0.00089
S28	0.299	0	
S29	0.3	0	
S30	0.298	0	
S31	0.3	0	
S32	0.3	0	
S33	0.3	0	
S34	0.298	0	
S35	0.3	0	
S36	0.3	0	
537	0.3	0	
538	0.3		
S39	0.3	0	
S40	0.297	0	
S41	0.3	0	
S42	0.299	0	
SD = Standa	ard Deviation		

Table 2: Clinical Test Results for PE Nucleic Acid Detection Kit and Kaya17 nCoVega Test

Sample	Date of onset of sympto ms	#of days Post sympto m	N Gene	IC	ORF1ab	PE RESULT	Kaya17 (RFU)	Kaya17 RESULT	Operator
NP-1	-	No Sympto m	UND	36.77	UND	NOT DETECTED	0.275	NEG	
NP-2	24-May- 21	1 day	30.05	33.47	30.07	DETECTED	0.392	POS	
NP-3	-	No Sympto m	UND	33.84	UND	NOT DETECTED	0.266	NEG	
NP-4	-	No Sympto m	UND	32.56	UND	NOT DETECTED	0.268	NEG	
NP-5	-	No Sympto m	UND	33.47	UND	NOT DETECTED	0.289	NEG	
NP-6	-	No Sympto m	UND	34.90	UND	NOT DETECTED	0.292	NEG	1
NP-7	-	No Sympto m	UND	33.59	UND	NOT DETECTED	0.284	NEG	1
NP-8	23-May- 21	2 Days	22.87	33.53	22.67	DETECTED	0.64	POS	
NP-9	-	No Sympto m	UND	33.64	UND	NOT DETECTED	0.281	NEG	
NP-10	23-May- 21	2 Days	30.59	35.99	31.96	DETECTED	0.293	NEG	
NP-11	23-May- 21	2 Days	31.49	33.79	UND	DETECTED	0.385	POS	
NP-12	22-May- 21	3 Days	33.10	33.56	35.57	DETECTED	0.382	POS	
NP-13	-	No Sympto m	24.81	33.01	25.53	DETECTED	0.562	POS	

	24-May-	1 day]				
NP-14	21 11111	1 day	29.64	34.02	29.71	DETECTED	0.396	POS
NID 45	23-May-	2 Days	10.02	22.21	20 71			
NP-15	21		19.83	32.21	20.71	DETECTED	0.767	POS
	-	No				NOT		
NP-16		Sympto	UND	31.14	UND	DETECTED		
		m					0.279	NEG
NP-17	-	No Sympto	UND	33.67	UND	NOT		
111-17		m	OND	33.07	OND	DETECTED	0.284	NEG
_	-	No						
NP-18		Sympto	UND	33.15	UND	NOT		
		m				DETECTED	0.278	NEG
NP-19	23-May-	2 Days	27.92	32.49	23.68	DETECTED		
	21						0.446	POS
NP-20	24-May- 21	1 day	UND	33.75	UND	NOT DETECTED	0.288	NEG
	22-May-	3 Days				DETECTED	0.200	NEG
NP-21	21	3 Days	32.94	33.16	34.98	DETECTED	0.383	POS
	-	No				NOT		
NP-22		Sympto	UND	32.56	UND	NOT DETECTED		
		m				DETECTED	0.295	NEG
NP-23	22-May-	3 Days	17.86	33.58	17.55	DETECTED		
	21	N					0.845	POS
NP-24	-	No Sympto	UND	33.63	UND	NOT		
111-24		m	OND	33.03	OND	DETECTED	0.287	NEG
	-	No						
NP-25		Sympto	UND	32.89	UND	NOT		
		m				DETECTED	0.293	NEG
	-	No				NOT		
NP-26		Sympto	UND	34.45	UND	DETECTED	0.27	
	22.14	2 Davis					0.276	NEG
NP-27	22-May- 21	3 Days	27.42	33.36	26.99	DETECTED	0.448	POS
		No					0.110	
NP-28		Sympto	UND	33.31	UND	NOT		
		m				DETECTED	0.296	NEG
NP-29	24-May-	1 day	32.99	32.23	34.33	DETECTED		
	21				200	1112123	0.388	POS

NP-30	22-May- 21	3 Days	19.55	33.49	19.75	DETECTED	0.763	POS	
NP-31	-	No Sympto m	UND	31.48	UND	NOT DETECTED	0.323	POS	
NP-32	-	No Sympto m	UND	32.89	UND	NOT DETECTED	0.293	NEG	
NP-33	-	No Sympto m	UND	33.02	UND	NOT DETECTED	0.278	NEG	
NP-34	22-May- 21	3 Days	28.52	33.94	28.70	DETECTED	0.38	POS	
NP-35	22-May- 21	3 Days	33.95	33.58	34.86	DETECTED	0.376	POS	
NP-36	-	No Sympto m	UND	34.46	UND	NOT DETECTED	0.278	NEG	
NP-37	-	No Sympto m	UND	33.92	UND	NOT DETECTED	0.294	NEG	
NP-38	-	No Sympto m	UND	32.53	UND	NOT DETECTED	0.288	NEG	
NP-39	25-May- 21	3 Days	28.82	35.67	28.30	DETECTED	0.401	POS	
NP-40	27-May- 21	1 day	UND	36.41	UND	NOT DETECTED	0.287	NEG	2
NP-41	-	No Sympto m	UND	33.23	UND	NOT DETECTED	0.298	NEG	
NP-42	-	No Sympto m	UND	32.34	UND	NOT DETECTED	0.272	NEG	
NP-43	-	No Sympto m	UND	33.63	UND	NOT DETECTED	0.284	NEG	
NP-44	-	No Sympto m	UND	32.22	UND	NOT DETECTED	0.281	NEG	

		No						I
NP-45	_	Sympto	UND	34.12	UND	NOT DETECTED	0.293	NEG
NP-46	-	No Sympto m	UND	33.41	UND	NOT DETECTED	0.285	NEG
NP-47	-	No Sympto m	UND	33.30	UND	NOT DETECTED	0.296	NEG
NP-48	-	No Sympto m	UND	33.20	UND	NOT DETECTED	0.294	NEG
NP-49	-	No Sympto m	UND	33.46	UND	NOT DETECTED	0.294	NEG
NP-50	-	No Sympto m	UND	34.85	UND	NOT DETECTED	0.281	NEG
NP-51	-	No Sympto m	UND	33.56	UND	NOT DETECTED	0.283	NEG
NP-52	-	No Sympto m	UND	32.66	UND	NOT DETECTED	0.289	NEG
NP-53	-	No Sympto m	UND	33.96	UND	NOT DETECTED	0.288	NEG
NP-54	27-May- 21	1 day	34.32	32.80	34.16	DETECTED	0.375	POS
NP-55	-	No Sympto m	UND	33.93	UND	NOT DETECTED	0.279	NEG
NP-56	26-May- 21	2 Days	35.10	32.53	35.91	DETECTED	0.379	POS
NP-57	25-May- 21	3 Days	18.76	33.67	19.82	DETECTED	0.817	POS
NP-58	27-May- 21	1 day	34.40	32.93	33.86	DETECTED	0.387	POS

ı				1				l	1
NP-59	-	No Sympto m	UND	32.79	UND	NOT DETECTED	0.286	NEG	
NP-60	-	No Sympto m	UND	34.54	UND	NOT DETECTED	0.294	NEG	
NP-61	-	No Sympto m	UND	33.64	UND	NOT DETECTED	0.287	NEG	
NP-62	-	No Sympto m	UND	35.73	UND	NOT DETECTED	0.295	NEG	
NP-63	-	No Sympto m	UND	33.16	UND	NOT DETECTED	0.291	NEG	
NP-64	-	No Sympto m	UND	35.99	UND	NOT DETECTED	0.296	NEG	
NP-65	-	No Sympto m	UND	32.35	UND	NOT DETECTED	0.279	NEG	
NP-66	-	No Sympto m	UND	33.90	UND	NOT DETECTED	0.289	NEG	
NP-67	-	No Sympto m	UND	34.65	UND	NOT DETECTED	0.293	NEG	
NP-68	3-Jun-21	2 Days	23.55	33.55	24.67	DETECTED	0.675	POS	
NP-69	4-Jun-21	1 day	34.74	32.82	35.92	DETECTED	0.377	POS	
NP-70	2-Jun-21	3 Days	25.66	33.78	UND	DETECTED	0.555	POS	
NP-71	3-Jun-21	2 Days	26.11	33.00	28.00	DETECTED	0.479	POS	3
NP-72		No Sympto m	UND	34.75	UND	NOT DETECTED	0.288	NEG	
NP-73	-	No Sympto m	UND	35.03	UND	NOT DETECTED	0.284	NEG	
NP-74	-	No Sympto m	35.16	33.87	36.84	DETECTED	0.368	POS	

NP-75	4-Jun-21	1 day	35.30	33.85	33.48	DETECTED	0.379	POS
NP-76	-	No Sympto m	UND	35.00	UND	NOT DETECTED	0.288	NEG
NP-77	-	No Sympto m	UND	34.78	UND	NOT DETECTED	0.292	NEG
NP-78	-	No Sympto m	UND	33.98	UND	NOT DETECTED	0.296	NEG
NP-79	-	No Sympto m	UND	35.67	UND	NOT DETECTED	0.289	NEG
NP-80	-	No Sympto m	UND	34.79	UND	NOT DETECTED	0.293	NEG
NP-81	-	No Sympto m	39.23	33.18	UND	DETECTED	0.329	POS
NP-82	3-Jun-21	2 Days	35.63	33.12	34.82	DETECTED	0.366	POS
NP-83	-	No Sympto m	UND	34.63	UND	NOT DETECTED	0.287	NEG
NP-84	-	No Sympto m	UND	34.56	UND	NOT DETECTED	0.276	NEG
NP-85	-	No Sympto m	UND	33.78	UND	NOT DETECTED	0.293	NEG
NP-86	3-Jun-21	2 Days	18.87	34.01	19.05	DETECTED	0.842	POS
NP-87	3-Jun-21	2 Days	25.12	33.43	24.93	DETECTED	0.528	POS
NP-88	3-Jun-21	2 Days	26.76	33.72	26.40	DETECTED	0.492	POS
NP-89	-	No Sympto m	UND	32.91	UND	NOT DETECTED	0.294	NEG
NP-90	-	No Sympto m	UND	33.54	UND	NOT DETECTED	0.296	NEG
NP-91	4-Jun-21	1 day	33.74	31.96	34.55	DETECTED	0.39	POS
NP-92	3-Jun-21	2 Days	28.52	33.60	29.88	DETECTED	0.421	POS

NP-93	4-Jun-21	1 day	35.47	33.66	35.45	DETECTED	0.376	POS	
NP-94	3-Jun-21	2 Days	22.45	33.41	21.77	DETECTED	0.674	POS	
NP-95	-	No Sympto m	UND	33.03	UND	NOT DETECTED	0.286	NEG	
NP-96	-	No Sympto m	UND	32.91	UND	NOT DETECTED	0.288	NEG	
NP-97	-	No Sympto m	UND	35.30	UND	NOT DETECTED	0.294	NEG	
NP-98	-	No Sympto m	UND	33.84	UND	NOT DETECTED	0.295	NEG	
NP-99	-	No Sympto m	UND	34.77	UND	NOT DETECTED	0.293	NEG	
NP-100	5-Jun-21	1 day	34.33	32.07	34.50	DETECTED	0.374	POS	
NP-101	5-Jun-21	1 day	UND	32.10	UND	NOT DETECTED	0.295	NEG	
NP-102	-	No Sympto m	UND	32.21	UND	NOT DETECTED	0.296	NEG	
NP-103	-	No Sympto m	UND	32.42	UND	NOT DETECTED	0.287	NEG	
NP-104	5-Jun-21	1 day	34.46	32.29	34.85	DETECTED	0.371	POS	4
NP-105	-	No Sympto m	37.67	32.55	38.11	DETECTED	0.368	POS	
NP-106	-	No Sympto m	UND	31.77	UND	NOT DETECTED	0.288	NEG	
NP-107	-	No Sympto m	UND	34.54	UND	NOT DETECTED	0.279	NEG	
NP-108	-	No Sympto m	UND	33.32	UND	NOT DETECTED	0.293	NEG	

		No]				I
NP-109	-	Sympto	UND	33.65	UND	NOT		
111 -109		m	OND	33.03	OND	DETECTED	0.294	NEG
NP-110	5-Jun-21	1 day	35.98	32.73	36.01	DETECTED	0.366	POS
NP-111	4-Jun-21	2 Days	34.66	33.21	34.97	DETECTED	0.37	POS
NP-112	4-Jun-21	2 Days	26.43	34.88	27.98	DETECTED	0.487	POS
NP-113	4-Jun-21	2 Days	30.12	31.44	UND	DETECTED	0.396	POS
NP-114	-	No Sympto m	UND	32.28	UND	NOT DETECTED	0.285	NEG
NP-115	-	No Sympto m	UND	32.69	UND	NOT DETECTED	0.296	NEG
NP-116	-	No Sympto m	UND	34.55	UND	NOT DETECTED	0.288	NEG
NP-117	-	1 day	UND	33.99	UND	NOT DETECTED	0.329	POS
NP-118	-	No Sympto m	UND	33.24	UND	NOT DETECTED	0.295	NEG
NP-119	-	No Sympto m	UND	33.40	UND	NOT DETECTED	0.293	NEG
NP-120	-	No Sympto m	UND	32.59	UND	NOT DETECTED	0.289	NEG
NP-121	5-Jun-21	1 day	31.54	32.73	30.98	DETECTED	0.387	POS
NP-122	4-Jun-21	2 Days	33.39	33.11	33.28	DETECTED	0.379	POS
NP-123	-	No Sympto m	UND	36.46	UND	NOT DETECTED	0.297	NEG
NP-124	2-Jun-21	4 days	22.85	33.26	22.37	DETECTED	0.646	POS
NP-125	-	No Sympto m	UND	33.55	UND	NOT DETECTED	0.288	NEG
NP-126	-	No Sympto m	UND	31.67	UND	NOT DETECTED	0.285	NEG

NP-127	-	No Sympto m	UND	34.21	UND	NOT DETECTED	0.295	NEG	
NP-128	-	No Sympto m	UND	33.44	UND	NOT DETECTED	0.296	NEG	
NP-129	-	No Sympto m	UND	32.45	UND	NOT DETECTED	0.292	NEG	
NP-130	3-Jun-21	3 Days	14.73	32.65	15.10	DETECTED	1.272	POS	
NP-131	5-Jun-21	1 day	21.58	33.32	21.99	DETECTED	0.683	POS	
NP-132	5-Jun-21	1 day	33.97	33.48	35.56	DETECTED	0.384	POS	
NP-133	4-Jun-21	2 Days	35.25	33.77	36.95	DETECTED	0.368	POS	
NP-134	4-Jun-21	2 Days	32.89	34.25	34.22	DETECTED	0.381	POS	
NP-135	5-Jun-21	1 day	35.33	33.92	35.02	DETECTED	0.374	POS	
NP-136	-	No Sympto m	37.74	34.67	38.08	DETECTED	0.361	POS	
NP-137	23-Jun- 21	4 days	15.76	32.69	15.59	DETECTED	0.921	POS	
NP-138	-	No Sympto m	UND	32.29	UND	NOT DETECTED	0.285	NEG	
NP-139	-	No Sympto m	UND	31.90	UND	NOT DETECTED	0.296	NEG	
NP-140	-	No Sympto m	UND	32.65	UND	NOT DETECTED	0.293	NEG	5
NP-141	-	No Sympto m	UND	32.98	UND	NOT DETECTED	0.297	NEG	
NP-142	25-Jun- 21	2 Days	35.17	32.28	34.66	DETECTED	0.327	POS	
NP-143	-	No Sympto m	UND	33.58	UND	NOT DETECTED	0.295	NEG	
NP-144	25-Jun- 21	2 Days	33.75	33.88	33.21	DETECTED	0.384	POS	

				1				
NP-145	24-Jun- 21	3 Days	33.76	32.55	34.86	DETECTED	0.388	pos
NP-146	24-Jun- 21	3 Days	29.58	33.75	29.57	DETECTED	0.397	POS
NP-147	24-Jun- 21	3 Days	21.65	33.45	21.50	DETECTED	0.683	POS
NP-148	-	No Sympto m	39.00	32.71	37.06	DETECTED	0.328	POS
NP-149	-	No Sympto m	UND	31.90	UND	NOT DETECTED	0.296	NEG
NP-150	25-Jun- 21	2 Days	34.79	32.56	36.85	DETECTED	0.374	POS
NP-151	25-Jun- 21	2 Days	35.02	32.32	34.62	DETECTED	0.377	POS
NP-152	-	No Sympto m	UND	34.56	UND	NOT DETECTED	0.293	NEG
NP-153	-	No Sympto m	UND	33.67	UND	NOT DETECTED	0.293	NEG
NP-154	-	No Sympto m	UND	33.84	UND	NOT DETECTED	0.287	NEG
NP-155	25-Jun- 21	2 Days	35.22	32.18	36.37	DETECTED	0.374	POS
NP-156	26-Jun- 21	1 day	34.82	33.00	34.67	DETECTED	0.375	POS
NP-157	26-Jun- 21	1 day	34.48	32.91	34.44	DETECTED	0.372	POS
NP-158	-	No Sympto m	UND	33.10	UND	NOT DETECTED	0.296	NEG
NP-159	-	No Sympto m	UND	33.87	UND	NOT DETECTED	0.293	NEG
NP-160	-	No Sympto m	UND	33.04	UND	NOT DETECTED	0.295	NEG

NP-161	
DETECTED 0.2 26-Jun- 1 day NOT	I
26-Jun- 1 day NOT	294 NEG
NP-162 26-Jun- 1 day JIND 33.46 JIND NOT	194 NEG
OTTO OTTO OTTO OTTO	NEC NEC
	295 NEG
NP-163 - No Sympto UND 33.85 UND NOT	
DETECTED	297 NEG
- No	NEG
NP-164 Sympto UND 34.06 UND NOT	
DETECTED	294 NEG
- No	INLO
NP-165 Sympto UND 31.54 UND NOT	
DETECTED	295 NEG
26-Jun- 1 day	1120
NP-166 36.03 33.01 34.70 DETECTED	B65 POS
26-Jun- 1 day	100
NP-167 UND 30.97 38.06 DETECTED	POS
25-Jun- 2 Days	100
NP-168 UND 33.15 38.87 DETECTED	POS POS
25-Jun- 2 Days	100
NP-169 35.31 32.80 35.16 DETECTED	POS
26-Jun- 1 day	70
NP-170 37.82 33.47 38.92 DETECTED	B65 POS
25-Jun- 2 Days	
NP-171 30.79 34.47 29.69 DETECTED	POS
24-Jun- 3 Days	100
NP-172 31.62 33.25 32.08 DETECTED	POS
- No	100
NP-173 Sympto UND 36.19 UND NOT	
DETECTED	297 NEG
24-Jun- 3 Days	1,20
NP-174 21 26.75 34.21 26.73 DETECTED 0.4	POS
23-Jun- 4 Days	
NP-175 27.52 33.68 27.59 DETECTED	POS
22-Jun- 5 Days	100
NP-176 29.30 34.07 29.27 DETECTED	998 POS
- No	
NP-177 Sympto UND 33.13 UND NOT	
DETECTED	293 NEG

399 400 401

NP-178	26-Jun- 21	1 day	33.56	33.41	36.53	DETECTED	0.38	POS	
NP-179	26-Jun- 21	1 day	35.30	32.72	35.66	DETECTED	0.372	POS	
NP-180	25-Jun- 21	2 Days	34.86	33.66	36.34	DETECTED	0.369	POS	
NP-181	25-Jun- 21	2 Days	35.80	33.63	37.02	DETECTED	0.364	POS	
NP-182	-	No Sympto m	UND	34.56	UND	NOT DETECTED	0.292	NEG	
NP-183	-	No Sympto m	UND	33.55	UND	NOT DETECTED	0.297	NEG	

UND=Undetected, NEG=Negative, POS=Positive